Sponsors (2)
Introduced March 6, 2025 by Ronald Lee Wyden · Last progress March 6, 2025
The bill invests substantially in health care access, public‑health preparedness, and drug‑price transparency—potentially improving care and lowering drug costs for many—while imposing sizable new reporting/compliance duties, privacy risks, and bigger federal spending commitments that may shift costs or pains onto states, plans, providers, and taxpayers.
Millions of patients, employers, and plan members: the bill forces far more PBM and drug‑price transparency (rebates, net drug prices, per‑claim data, PBM pass‑through rules and audits), giving consumers, employers, and regulators better information to identify high‑cost drugs and negotiate lower prices.
Low‑income, uninsured, and rural communities: the bill provides large, multi‑year increases and short‑term transitional funding for community health centers, the National Health Service Corps, teaching health center GME, and targeted disease programs (diabetes, WTC Health Program, sickle cell, breast/cervical cancer, dental), supporting primary care access and workforce capacity.
Patients and public health: the bill boosts preparedness and surveillance capacity by funding Hospital Preparedness Programs, regional biocontainment labs, wastewater surveillance grants, AMR strategy and diagnostic preparedness, and related training, improving readiness for pandemics and other biological threats.
Taxpayers and federal budget: the bill increases authorizations and new program funding across many public‑health, community health, preparedness, and program areas, raising federal outlays and adding to budgetary pressure absent offsets.
States, plans, providers, pharmacies, and small businesses: the bill creates widespread new reporting, auditing, and data‑collection requirements (PBMs, pharmacies, hospitals, state Medicaid agencies, grantees), imposing significant administrative and compliance burdens that may be passed to consumers or reduce provider/plan capacity.
Patients and consumers: the compliance costs and operational shifts required of PBMs, plans, pharmacies, and small providers could be passed through as higher premiums, cost‑sharing, or reduced benefits, offsetting some intended savings for enrollees.
Based on analysis of 36 sections of legislative text.
Broad health‑system reforms: streamlines out‑of‑State Medicaid provider enrollment for children, imposes PBM transparency/reporting, adjusts Medicare/Medicaid payment rules, and funds multiple public‑health programs.
Requires many health-sector reforms and new reporting rules, increases targeted public‑health funding, and changes drug, patent, and hospital payment rules. Key changes include streamlining Medicaid enrollment for eligible out‑of‑State providers treating children on Medicaid, new reporting and transparency requirements for pharmacy benefit managers (PBMs) in Part D and for group health plans, Medicare Advantage provider‑directory accuracy requirements, caps on patents asserted in certain biosimilar suits, date shifts/extensions for some Medicare hospital payment rules, and multi‑year funding/reauthorizations for community health centers, teaching health centers, and other public health programs. Imposes new data/reporting duties on States, plans, PBMs, and manufacturers; authorizes and specifies multiple appropriations for FY2025–FY2029 and creates several new programs (regional biocontainment labs, maternal‑health study, expanded surveillance/overdose programs). Many provisions take effect on staggered dates (some months/years after enactment).